Sepsis Diagnostics Market Trends and Analysis Report 2022-2032

Posted by Ganesh Shinde on January 11th, 2023

According to a recent Future Market Insights report, the Global Sepsis Diagnostics Market is expected to reach US$ 1.3 billion by 2032. It is also expected to grow at a CAGR of 9% over the forecast period. The increased prevalence of sepsis, the development of technologically advanced diagnostic methods, and expanding government programmes are expected to increase the number of active sepsis diagnostics companies over the forecast period.

Because of increased demand for antibiotic-resistant bacterial strains, an ageing population, and a high prevalence of hospital-acquired infection, the sector is booming. Furthermore, an increase in the proportion of product approvals for sepsis diagnosis is expected to boost demand for sepsis diagnostics.

However, factors such as a lack of experienced specialists for diagnosing sepsis, a lack of knowledge, and the use of traditional antibiotic production processes impede the sale of sepsis diagnostics.

Because of the increase in newborn umbilical cord infection cases and surgical procedures in these countries, developing markets offer a promising future for sepsis diagnostics.

HAIs, also known as nosocomial infections, are a significant cause of morbidity and mortality in hospitals worldwide. The most common hospital-acquired infections are urinary tract infections, pneumonia, and sepsis (HAIs). HAIs can also cause sepsis in immunocompromised people, the elderly, and people with chronic conditions. Because of the significant increase in HAIs worldwide, demand for sepsis diagnostic devices is expected to grow in the coming years.

Sepsis is a difficult condition to diagnose, and even a one-minute delay in antibiotic delivery increases the risk of death in septic shock patients with hypertension by 7.6%. Because of emerging trends in the sepsis diagnostics market, there is a greater need for rapid sepsis detection in order to avoid antibiotic therapy delays in sepsis patients.

Many sepsis diagnostic companies are expanding their product offerings in point-of-care technologies, which can quickly identify sepsis, reduce diagnosis time, and improve post-sepsis life expectancy.

The global market for sepsis diagnostics is expected to reach US$ 770 Mn by 2026.

Key Takeaways

• The Asia Pacific region of rapid sepsis diagnostics is expected to grow profitably over the forecast period, owing to the presence of a larger consumer population in developing markets such as India and China.
• Adoption trends in the global sepsis diagnostics market indicate that North America will generate more than 0 million in revenue by the end of 2026. The region's sepsis diagnostics companies are expanding as a result of well-established healthcare infrastructure and increased use of innovative products. In addition, septic poisoning is one of the leading causes of death in the United States.
• According to a market analysis of sepsis diagnostics, microbiology technology is likely to gain traction. By 2026, microbiology is expected to generate more than 0 million in revenue.
• The sepsis diagnostics market is segmented by product into blood culture media, assays & reagent kits, devices, and software. During the forecast period, the blood culture media segment held the largest market share. This expansion can be attributed to an increase in the use of blood culture media as a sepsis diagnostic device.

“The cost of sepsis diagnostic devices limits the industry's growth. Furthermore, in some countries, there are no clear guidelines for the treatment of sepsis, and there is a lack of awareness about the consequences of untreated sepsis.”

Browse More@ https://www.futuremarketinsights.com/reports/sepsis-diagnostics-market

Competitive Landscape

To gain a competitive advantage and generate significant profits, organisations in the global quality articulation market are consolidating and acquiring systems. Some players, on the other hand, benefit from significant new work systems in order to gain a competitive advantage in the sepsis diagnostics market statistics.

• In April 2020, Cytovale Inc. and the Biomedical Advanced Research and Development Authority, or BARDA, announced a collaboration to expand the use of Cytovale's Rapid Sepsis Diagnostic System for identifying sepsis in patients with probable respiratory infections, such as COVID-19.
• Immunexpress plans to launch a one-hour molecular diagnostic test for sepsis, SeptiCyte, on Biocartis' Idylla platform in Europe in October 2020. This is one of the first deeply integrated, immune response-based diagnostics to aid clinicians in the diagnosis of sepsis.

Key Segments

By Product:

• Blood Culture Media
• Assays & Reagents
• Instruments, and Software

By Technology:

• Blood Culture
• Immunoassays
• Molecular Diagnostics
• Flow Cytometry
• Microfluidics
• Biomarkers

By Method:

• Automated Diagnostics
• Conventional Diagnostics

By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

By Test Type:

• Laboratory Tests
• Point-of-Care Tests

By End User:

• Hospitals and Specialty Clinics
• Pathology & Reference Laboratories
• Research Laboratories & Academic Institutes